title: Deregulation of lipid metabolism pathway genes in nasopharyngeal carcinoma             cells.
abstract: Nasopharyngeal carcinoma (NPC) is a unique tumour of epithelial origin with             a distinct geographical distribution, closely associated with the Epstein‑Barr             virus (EBV). EBV‑encoded RNAs (EBERs) are small non‑polyadenylated RNAs that are             abundantly expressed in latent EBV‑infected NPC cells. To study the role of EBERs             in NPC, we established stable expression of EBERs in HK1, an EBV‑negative NPC             cell line. Cells expressing EBERs consistently exhibited an increased growth rate.             However, EBERs did not confer resistance towards cisplatin‑induced apoptosis or             promote migration or invasion ability in the cells tested. Using microarray gene             expression profiling, we identified potential candidate genes that were deregulated             in NPC cells expressing EBERs. Gene Ontology analysis of the data set revealed             that EBERs upregulate the cellular lipid metabolic process. Upregulation of low‑density             lipoprotein receptor (LDLR) and fatty acid synthase (FASN) was observed in EBER‑expressing             cells. NPC cells exhibited LDL‑dependent cell proliferation. In addition, a polyphenolic             flavonoid compound, quercetin, known to inhibit FASN, was found to inhibit proliferation             of NPC cells.
authors.affiliation: Molecular Pathology Unit, Cancer Research Centre, Institute for                     Medical Research, Kuala Lumpur 50588, Malaysia.
authors.forename: Maelinda
authors.initials: M
authors.lastname: Daker
authors.forename: Saatheeyavaane
authors.initials: S
authors.lastname: Bhuvanendran
authors.forename: Munirah
authors.initials: M
authors.lastname: Ahmad
authors.forename: Kenzo
authors.initials: K
authors.lastname: Takada
authors.forename: Alan Soo-Beng
authors.initials: AS
authors.lastname: Khoo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use; D064429:Fatty Acid Synthases / Q000378:metabolism; D020869:Gene Expression Profiling; D004854:Herpesvirus 4, Human / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000235:genetics*; D051379:Mice; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011794:Quercetin / Q000494:pharmacology; D012367:RNA, Viral / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism; D014183:Transplantation, Heterologous; D015854:Up-Regulation / Q000187:drug effects; D014763:Viral Matrix Proteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D012367:RNA, Viral; D011973:Receptors, LDL; D014763:Viral Matrix Proteins; D011794:Quercetin; D064429:Fatty Acid Synthases; D002945:Cisplatin